Physician profile
Daniel J Gurley
NPI 1952339749
$2,483.83
in general payments reported to CMS, 2019-2025
20 companies · $968 in 2025
The $968 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $46.37 · 2021: $12.20 · 2022: $296 · 2023: $607 · 2024: $411 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $642.91 | 2019-2025 | Euflexxa |
| Smith+Nephew, INC. | $494.41 | 2024-2025 | Bone Anchors With Arthroscopic Delivery System, N/A, Evos |
| Restor3d, INC. | $244.20 | 2022 | |
| Stryker Corporation | $194.55 | 2024-2025 | Iconix, Champion, Inspace |
| Titan Surgical Group, LLC | $149.90 | 2023 | |
| Anika Therapeutics, INC. | $147.37 | 2023 | Tactoset, X-Twist |
| Depuy Synthes Sales INC. | $141.18 | 2023-2025 | Inhance, Peak, Monovisc |
| Vericel Corporation | $118.22 | 2022-2025 | Maci |
| Linvatec Corporation | $113.62 | 2023 | Biobrace 23mm |
| Amgen INC. | $62.70 | 2019-2020 | |
| Bioventus LLC | $34.11 | 2024-2025 | Durolane, Xcell |
| Fidia Pharma USA INC. | $23.46 | 2025 | Hymovis |
| Kerecis Limited | $21.62 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Valencia Technologies Corporation | $15.95 | 2025 | Ecoin Device Kit |
| Amarin Pharma, INC. | $15.14 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.83 | 2019 | |
| Glaxosmithkline, LLC. | $13.50 | 2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $12.93 | 2019 | |
| Linkbio Corp | $12.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.